Carisma therapeutics announces first patient dosed in phase 1 clinical trial of ct-0525, a novel her2-targeting car-monocyte

Ct-0525 is the first car-monocyte to be evaluated in humans in the solid tumor setting initial data expected by year-end 2024 philadelphia , may 16, 2024 /prnewswire/ -- carisma therapeutics inc. (nasdaq: carm) ("carisma" or the "company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the first patient was dosed in its phase 1 clinical trial evaluating ct-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (car-monocyte) cellular therapy, for the treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2 (her2). "dosing of the first patient in the ct-0525 phase 1 trial is a significant step in the development of engineered myeloid cells, marking the first time a car-monocyte is tested in humans in the solid tumor setting," said eugene p.
CAR Ratings Summary
CAR Quant Ranking